A Phase 2 interventional study of Fenretinide in Geographic Atrophy and Dry Age Related Macular Degeneration, sponsored by Sirion Therapeutics, Inc.. Completed. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2010-06-22.
Sponsored by Sirion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
This study's enrollment of 245 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Browse Geographic Atrophy studies →Sirion Therapeutics, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Three (3) 100-mg fenretinide softgel capsules
Drug: Fenretinide
One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
Drug: Fenretinide
Three (3) placebo softgel capsules
Drug: Fenretinide
Once daily 30 minutes after the evening meal for 24 months
GA lesion progression
Time frame: 1 year
No study locations are listed for this record.
The record gives a start of Dec 2006, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenretinide
Sirion Therapeutics, Inc.